These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 759880)

  • 1. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
    Alexander J; Dainiak N; Berger HJ; Goldman L; Johnstone D; Reduto L; Duffy T; Schwartz P; Gottschalk A; Zaret BL
    N Engl J Med; 1979 Feb; 300(6):278-83. PubMed ID: 759880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
    Schwartz RG; McKenzie WB; Alexander J; Sager P; D'Souza A; Manatunga A; Schwartz PE; Berger HJ; Setaro J; Surkin L
    Am J Med; 1987 Jun; 82(6):1109-18. PubMed ID: 3605130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance.
    Choi BW; Berger HJ; Schwartz PE; Alexander J; Wackers FJ; Gottschalk A; Zaret BL
    Am Heart J; 1983 Oct; 106(4 Pt 1):638-43. PubMed ID: 6613807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
    Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
    J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective right ventricular dysfunction following doxorubicin therapy.
    Sperber AD; Cantor AA; Biran H; Keynan A
    Isr J Med Sci; 1987 Aug; 23(8):896-9. PubMed ID: 3679793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
    Nousiainen T; Jantunen E; Vanninen E; Hartikainen J
    Br J Cancer; 2002 Jun; 86(11):1697-700. PubMed ID: 12087452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity.
    Steinberg JS; Wasserman AG
    Clin Ther; 1985; 7(6):660-7. PubMed ID: 3907840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.
    Mitani I; Jain D; Joska TM; Burtness B; Zaret BL
    J Nucl Cardiol; 2003; 10(2):132-9. PubMed ID: 12673177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
    Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
    Am J Med; 1985 Apr; 78(4):555-63. PubMed ID: 3838618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
    Speyer JL; Green MD; Kramer E; Rey M; Sanger J; Ward C; Dubin N; Ferrans V; Stecy P; Zeleniuch-Jacquotte A
    N Engl J Med; 1988 Sep; 319(12):745-52. PubMed ID: 3137469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography.
    Suzuki J; Yanagisawa A; Shigeyama T; Tsubota J; Yasumura T; Shimoyama K; Ishikawa K
    Angiology; 1999 Jan; 50(1):37-45. PubMed ID: 9924887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gated blood pool scintigraphic monitoring of doxorubicin cardiomyopathy: comparison of camera and computerized probe results in 101 patients.
    Strashun AM; Goldsmith SJ; Horowitz SF
    J Am Coll Cardiol; 1986 Nov; 8(5):1082-7. PubMed ID: 3760382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radionuclide ejection fraction in doxorubicin cardiotoxicity.
    Morgan GW; McIlveen BM; Freedman A; Murray IP
    Cancer Treat Rep; 1981; 65(7-8):629-38. PubMed ID: 7248982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of noninvasive cardiac parameters in the detection and evaluation of adriamycin cardiotoxicity.
    Shuman RD; Ettinger DS; Abeloff MD; Livengood SV; Fortuin NJ
    Johns Hopkins Med J; 1981 Aug; 149(2):57-63. PubMed ID: 7253365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adriamycin (doxorubicin) cardiotoxicity: a review.
    Chlebowski RT
    West J Med; 1979 Nov; 131(5):364-8. PubMed ID: 394479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
    Lipshultz SE; Colan SD; Gelber RD; Perez-Atayde AR; Sallan SE; Sanders SP
    N Engl J Med; 1991 Mar; 324(12):808-15. PubMed ID: 1997853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adriamycin and the heart.
    Henderson IC; Frei TE
    N Engl J Med; 1979 Feb; 300(6):310-2. PubMed ID: 759884
    [No Abstract]   [Full Text] [Related]  

  • 18. Monitoring cardiac function in patients receiving doxorubicin.
    Lu P
    Semin Nucl Med; 2005 Jul; 35(3):197-201. PubMed ID: 16098293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of tests for monitoring doxorubicin-induced cardiomyopathy.
    Ganz WI; Sridhar KS; Ganz SS; Gonzalez R; Chakko S; Serafini A
    Oncology; 1996; 53(6):461-70. PubMed ID: 8960141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography.
    Agarwala S; Kumar R; Bhatnagar V; Bajpai M; Gupta DK; Mitra DK
    J Pediatr Surg; 2000 Dec; 35(12):1786-9. PubMed ID: 11101737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.